<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03347188</url>
  </required_header>
  <id_info>
    <org_study_id>TV48125-CNS-20024</org_study_id>
    <nct_id>NCT03347188</nct_id>
  </id_info>
  <brief_title>A Study Comparing 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of PPTH</brief_title>
  <official_title>A Phase 2, Multicenter, Randomized, Proof-of-Concept, Double Blind, Placebo Controlled, Parallel Group Study Comparing the Efficacy and Safety of 1 Subcutaneous Dose Regimen of Fremanezumab Versus Placebo for the Prevention of Persistent Posttraumatic Headache (PPTH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Teva Branded Pharmaceutical Products, R&amp;D Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Teva Pharmaceutical Industries</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a 12-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group
      study to evaluate the safety and efficacy of fremanezumab in adult patients aged 18 to 70
      years, inclusive, for the prevention of PPTH. Patients will provide written informed consent
      and during study visits they will use an electronic diary application daily, to report their
      headache status and other health information. Efficacy and immunogenicity status will be
      captured periodically and at study termination. The safety will be evaluated through adverse
      event report, concomitant medication inquiries, ECGs, clinical laboratory tests and physical
      examination. Additional evaluations will include pharmacokinetic, biomarker, and
      pharmacogenomics.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 17, 2017</start_date>
  <completion_date type="Anticipated">April 7, 2019</completion_date>
  <primary_completion_date type="Anticipated">March 18, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>mean change in the monthly average number of headache days</measure>
    <time_frame>Baseline-Week 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>proportion of patients reaching at least 50% reduction in the monthly average number of headache days of any severity</measure>
    <time_frame>Baseline-Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in the number of headache days of at least moderate severity</measure>
    <time_frame>during the first 4-week period, the 5- to 8-week period, and the 9- to 12-week period after the first dose</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mean change in disability score, as measured by the 6-item Headache Impact Test (HIT-6)</measure>
    <time_frame>Baseline, Week 12 after the first dose</time_frame>
    <description>Six questions asked about the effect the headache has on normal daily life and ability to function. Each can be rated: Never (6 points), Rarely (8 points), Sometimes (10 points), Very often (11 points), Always (13 points). A higher total number represents a worse outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>occurrence of adverse events</measure>
    <time_frame>44 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of patients who did not complete the study</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number (%) of patients who did not complete the study due to adverse events</measure>
    <time_frame>Day 56</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">172</enrollment>
  <condition>Post-Traumatic Headache</condition>
  <arm_group>
    <arm_group_label>Fremanezumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>675 mg of fremanezumab administered as 3 sc injections (225 mg/1.5 mL each ) at week 0, week 4, and week 8.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>675 mg of placebo administered as 3 sc injections (225 mg/1.5 mL each ) at week 0,week, and week 8.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fremanezumab</intervention_name>
    <description>1 subcutaneous dose regimen</description>
    <arm_group_label>Fremanezumab</arm_group_label>
    <other_name>TEV-48125</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 subcutaneous dose regimen</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  The patient has a body weight is greater than 99 lbs.

          -  Traumatic injury to the head has occurred, defined as a structural or functional
             injury resulting from the action of external forces.

          -  The patient has a diagnosis of PPTH

          -  The patient is not using preventive medications for headache

          -  Women of childbearing potential whose male partners are potentially fertile (ie, no
             vasectomy) must use highly effective birth control methods for the duration of the
             study. Men must be sterile or, if they are potentially fertile or reproductively
             competent (ie, not surgically or congenitally sterile) and their female partners are
             of childbearing potential, must use, together with their female partners, acceptable
             birth control methods for the duration of the study.

        NOTE- Additional criteria apply, please contact the investigator for more information

        Exclusion Criteria:

          -  The patient has a previous history of brain imaging showing evidence of intracerebral
             hemorrhage, subdural or epidural hematomas, or subarachnoid hemorrhage as a
             consequence of the traumatic head injury.

          -  The patient has PPTH attributed to craniotomy.

          -  The patient has whiplash with only neck pain and no persistent headache &gt;3 months
             after whiplash.

          -  The patient is using analgesic medications containing opioids (including codeine) or a
             barbiturate on average more than 15 days per month.

          -  The patient is currently using or has prior exposure to any calcitonin gene-related
             peptide (CGRP) antibody, any antibody to the CGRP receptor.

          -  The patient has received onabotulinmumtoxinA (eg, Botox, Dysport) application in the
             head or neck during the previous 3 months before screening.

          -  The patient has been implanted with any devices for headache prophylaxis during the
             previous 3 months before screening.

          -  The patient has been treated with a nerve block for head and/or neck during the
             previous 3 months before screening.

          -  The patient is a pregnant or lactating woman or plans to become pregnant during the
             study.

        NOTE- Additional criteria apply, please contact the investigator for more information
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Teva Medical Expert, MD</last_name>
    <role>Study Director</role>
    <affiliation>TEVA</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Teva U.S. Medical Information</last_name>
    <phone>1-888-483-8279</phone>
    <email>USMedInfo@tevapharm.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Teva Investigational Site 14065</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85018</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>602-258-3354</phone>
      <email>levine865@aol.com; tlevine@pnal.net; angelina.cooper@honorhealth.com;angelina.cooper@honorhealth.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14048</name>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72205</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>501-224-1348</phone>
      <email>goodbrain@aol.com; research@bhccr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14052</name>
      <address>
        <city>Long Beach</city>
        <state>California</state>
        <zip>90806</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>714-799-7799</phone>
      <email>omidomidvar@cnstrial.com; annie@btheodore.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14053</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90073</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>818-439-6227</phone>
      <email>roiann.wallis@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14060</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>858-657-7030</phone>
      <email>ayleung@ucsd.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14054</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>415-673-4600</phone>
      <email>jboldstein@sfcrc.org ; sfhaclin@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14045</name>
      <address>
        <city>Fairfield</city>
        <state>Connecticut</state>
        <zip>06824</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>203-333-1151</phone>
      <email>ttoothaker@anscneuro.com; dzagar@anscneuro.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14063</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>305-243-6090</phone>
      <email>tmonteith@med.miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14041</name>
      <address>
        <city>North Miami</city>
        <state>Florida</state>
        <zip>33161</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>954-962-1355</phone>
      <email>ssegal@segalinstitute.com; ssegal@segaltrials.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14056</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>813-353-9613</phone>
      <email>sergay1@me.com; ssergay.axiom@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14057</name>
      <address>
        <city>Riverwoods</city>
        <state>Illinois</state>
        <zip>60015</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>847-374-9399</phone>
      <email>lrobb98@aol.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14067</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>317-537-6088</phone>
      <email>craig_herrman@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14058</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>502-899-6782</phone>
      <email>brian.plato@nortonhealthcare.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14061</name>
      <address>
        <city>Watertown</city>
        <state>Massachusetts</state>
        <zip>02472</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>617-636-5848</phone>
      <email>spierings@medvadis.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14051</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64128</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1 816 861 4700 (56622)</phone>
      <email>vikas.singh3@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14046</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>314-251-8890</phone>
      <email>jo.bonner@mercy.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14043</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65810</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>417-883-7889</phone>
      <email>tsmith@studymetrix.com; timothy.smith.md@gmail.com; timothy.smith@mercy.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14047</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>212-774-2138</phone>
      <email>shettyt@hss.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14059</name>
      <address>
        <city>Salisbury</city>
        <state>North Carolina</state>
        <zip>28144</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>704-638-9000</phone>
      <email>robin.hurley@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14049</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97225</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>503-216-1150</phone>
      <email>h.a.krob@providence.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14064</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>215-955-2243</phone>
      <email>michael.marmura@jefferson.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14040</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15236</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>+1-412-650-6155 (142)</phone>
      <email>nbennett18@ppcp.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14055</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390-9063</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <phone>214-648-0576</phone>
      <email>bert.vargas@utsouthwestern.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14050</name>
      <address>
        <city>Waco</city>
        <state>Texas</state>
        <zip>76711</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>254-752-6581</phone>
      <email>geoff.may@va.gov; geoffrey.may@va.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Teva Investigational Site 14044</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <phone>304-293-3527</phone>
      <email>unajib@hsc.wvu.edu</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 14, 2017</study_first_submitted>
  <study_first_submitted_qc>November 16, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 20, 2017</study_first_posted>
  <last_update_submitted>May 7, 2018</last_update_submitted>
  <last_update_submitted_qc>May 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>persistent posttraumatic headache (PPTH)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Headache</mesh_term>
    <mesh_term>Post-Traumatic Headache</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

